Company intelligence
Artis BioSolutions
Where Genetic Medicines Begin
About Artis BioSolutions
Advanced Therapies Are Only as Strong as the Materials Used to Create Them As the first company to combine proprietary synthetic DNA manufacturing with advanced therapy development and GMP manufacturing, Artis provides a connected path from starting material to clinical production. Our integrated platform helps genetic medicine developers move faster, reduce complexity, and maintain greater control throughout development. With operations in the United States and Europe, Artis supports programs spanning cell therapy, gene therapy, mRNA, gene editing, vaccines, and other advanced therapeutic modalities. By bringing synthetic DNA, process development, and GMP manufacturing together under one organization, we help transform promising science into clinical reality.
Verified activity
Signals from Artis BioSolutions
15 published signals
Presence & Recognition
Artis BioSolutions scheduled a talk on Synthetic DNA: Redefining the Economics of Advanced Therapies Manufacturing at 2:00pm tomorrow.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions opened Advanced Therapies Europe at the InterContinental in Barcelona.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions employee Kate Broderick was interviewed by ChEnected, AIChE's engineering community about technologies compressing drug development timelines.
Reported by Kate Broderick
Research & Knowledge
Artis BioSolutions published a piece on ChEnected, AIChE - American Institute of Chemical Engineers, discussing technologies compressing drug development timelines.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions is attending the Advanced Therapies Europe event in Barcelona from September 7-9 at the InterContinental.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions participated in the mRNA Process Development and CMC Summit at Boston from 30 September to 1 October with Kate Broderick presenting at the booth.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions participated in the San Diego to Japan Trade Mission event from 7 to 11 September with Kate Broderick joining the delegation.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions participated in the Asia Bio Partnering Forum at the Marina Bay Sands in Singapore from 1 to 2 September.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions participated in the Advanced Therapies Europe event at InterContinental Barcelona from 7 to 9 September with Ana Ricobaraza Abarquero Ph. D., Kris Ward, and José Vicente Pons Andreu presenting on Synthetic DNA.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions attended the Gene Therapy Initiative Symposium at the Salk Institute for Biological Studies in La Jolla on 16 September with Alma Ines O. and Emilia Gianfortoni Manzi attending.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions attended the CGT Symposium at the Salk Institute on 17 September with Alma Ines O. staying for day two.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions employee Julen Oyarzabal is attending the Asia Bio Partnering Forum at Marina Bay Sands today and tomorrow.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions sponsored the GEAR 2026 event at Boston from 15 to 17 September with Kate Broderick keynoting and Gregg Nyberg chairing a panel.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions presented at the BIOSPAIN event in Bilbao from 29 September to 1 October with Julen Oyarzabal presenting minutes from the synthetic DNA site.
Reported by Artis BioSolutions
Presence & Recognition
Artis BioSolutions will be attending Advanced Therapies Europe in Barcelona from September 7 to 9 at the InterContinental stand.
Reported by Kris Ward